Skip to search formSkip to main contentSkip to account menu

rivastigmine

Known as: Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1), (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate, M-((S)-1-(Dimethylamino)ethyl)phenyl Ethylmethylcarbamate 
A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in… 
National Institutes of Health

Related topics

Related topics

18 relations
24 HR rivastigmine 0.192 MG/HR Transdermal System24 HR rivastigmine 0.192 MG/HR Transdermal System [Exelon]Alzheimer's DiseaseCarbamates

Broader (2)

Cholinesterase InhibitorsNeuroprotective Agents

Narrower (1)

Exelon

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Report of the Quality Standards Subcommittee of the
  • 2010
  • Corpus ID: 8092396
Highly Cited
2009
Highly Cited
2009
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
Highly Cited
2009
Highly Cited
2009
Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery—A randomized controlled trial*
Objective:Cardiac surgery is frequently followed by postoperative delirium, which is associated with increased 1-year mortality… 
Review
2009
Review
2009
Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review
Background:  Cholinesterase inhibitors have all been available in oral formulations, but a rivastigmine transdermal patch has now… 
Highly Cited
2008
Highly Cited
2008
A study of rivastigmine liposomes for delivery into the brain through intranasal route
A study of rivastigmine liposomes for delivery into the brain through intranasal route The present study is mainly aimed at… 
Highly Cited
2007
Highly Cited
2007
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study
Highly Cited
2006
Highly Cited
2006
The anti‐amnesic and neuroprotective effects of donepezil against amyloid β25‐35 peptide‐induced toxicity in mice involve an interaction with the σ1 receptor
The acetylcholinesterase inhibitor, donepezil, is also a high affinity σ1 receptor agonist. We examined the involvement of σ1… 
Review
2005
Review
2005
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials
Abstract Objectives Pharmacological treatment of Alzheimer's disease focuses on correcting the cholinergic deficiency in the… 
Highly Cited
2005
Highly Cited
2005
Unequal Neuroprotection Afforded by the Acetylcholinesterase Inhibitors Galantamine, Donepezil, and Rivastigmine in SH-SY5Y Neuroblastoma Cells: Role of Nicotinic Receptors
Donepezil, rivastigmine, and galantamine are three drugs with acetylcholinesterase (AChE)-inhibiting activity that are currently… 
Highly Cited
2002
Highly Cited
2002
Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine.
Rivastigmine, a carbamate inhibitor of acetylcholinesterase, is already in use for treatment of Alzheimer's disease under the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)